羧甲司坦口服液联合氟替美维吸入粉雾剂治疗支气管哮喘的效果OA

Objective:To explore and analyze the clinical effect of Carbocysteine Oral Solution combined with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation in patients with bronchial asthma.Method:A total of 80 patients diagnosed with bronchial asthma admitted to the Department of Respiratory Medicine of Beijing Huairou Hospital from January to December 2024 were selected and divided into the observation group and the control group through the double-blind digital table protocol,with 40 cases in each group.Both groups received basic symptomatic treatment intervention.On this basis,the control group was treated with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation,while the observation group was treated with Carbocysteine Oral Solution combined with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation.The treatment course was 2 weeks.The asthma control test(ACT)scores,serum factor levels,sputum and mucus secretion indicators,and medication safety of the two groups were compared.Result:Compared with the control group,the observation group had higher ACT score after treatment(P<0.05).After treatment,levels of interferon-gamma(IFN-γ),leukotriene B4(LTB4),IL-6,and intercellular adhesion molecule-1(ICAM-1)in the observation group were all lower than those in the control group(P<0.05).After treatment,the observation group showed less daily sputum volume,lower sputum viscosity,and sputum mucin 5ac levels compared with the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment of Carbocysteine Oral Solution and Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation can effectively control the condition,relieve inflammatory responses,and reduce sputum secretion.The safety of medication is relatively high.